Illustration: Shutterstock

What more can we learn from DTC ad­ver­tis­ing? FDA's OPDP pro­pos­es new re­search

How do specifics around en­dorse­ments, mech­a­nism of ac­tion and med­ica­tion track­ing in phar­ma­ceu­ti­cal ads im­pact con­sumers? That’s what the FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) wants to find out in three new stud­ies.

OPDP has pro­posed three re­search projects on di­rect-to-con­sumer mar­ket­ing, ac­cord­ing to fed­er­al reg­is­ter no­tices post­ed last week. The stud­ies would join the agency’s ros­ter of 13 on­go­ing projects cov­er­ing a wide range of top­ics, from ac­cel­er­at­ed ap­proval dis­clo­sure to in­ter­pre­ta­tion of drug names.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.